icosapent ethyl / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 26 Diseases   7 Trials   7 Trials   4331 News 


«12...1011121314151617181920...5051»
  • ||||||||||  Parmodia (pemafibrate) / Kowa
    Clinical, Journal:  Managing dyslipidemia in patients with type 2 diabetes. (Pubmed Central) -  Nov 4, 2021   
    If LDL-C goals are not achieved, first, ezetimibe and subsequently proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors should be added...Fibrates should be used for severe hypertriglyceridemia to prevent acute pancreatitis. Novel treatments including pemafibrate and inclisiran are undergoing cardiovascular outcome trials and RNA-based therapies may help to target residual hypertriglyceridemia and high lipoprotein(a) with the long acting treatments offering potential improved adherence to therapy.
  • ||||||||||  Parmodia (pemafibrate) / Kowa
    Review, Journal:  Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline. (Pubmed Central) -  Nov 2, 2021   
    Currently, the only US Food and Drug Administration approved medication for CV risk reduction in patients with hypertriglyceridemia is icosapent ethyl. Results from phase 3 trials for CaPre, pemafibrate, and volanesorsen as well as additional evidence for pipeline pharmacotherapies with novel mechanisms of action (e.g., ApoC-III mRNA antisense inhibitors and ANGPTL3 antibodies) will help to guide future pharmacotherapy considerations for patients with hypertriglyceridemia.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Vazkepa is coming! (Twitter) -  Oct 30, 2021   
  • ||||||||||  icosapent ethyl / Generic mfg.
    Clinical, Review, Journal:  Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. (Pubmed Central) -  Oct 30, 2021   
    In addition, the REDUCE-IT study provides evidence for additional benefit from the use of high-dose icosapent ethyl (IPE) on top of background medical therapy in adults with moderate HTG and ASCVD or type 2 diabetes mellitus (T2D) and additional ASCVD risk factors...Acute pancreatitis is more difficult to study prospectively since it is less common; however, TG lowering is likely critical for the care of at-risk individuals. Additional benefit from novel therapy that has an impact on this otherwise refractory condition is anticipated.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Clinical, Journal:  Defining the Role of Icosapent Ethyl in Clinical Practice. (Pubmed Central) -  Oct 28, 2021   
    While this trial has been regarded as one of the most important landmark trials in preventive cardiology, the tolerability issue in a very high dose (4 g/day, as administered in the trial) is still a matter of concern. This article summarizes the current status and future perspective of icosapent ethyl in clinical practice in light of REDUCE-IT.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Clinical, Journal:  Translating evidence from clinical trials of omega-3 fatty acids to clinical practice. (Pubmed Central) -  Oct 27, 2021   
    The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) study recently demonstrated that administration of high doses of omega-3 fatty acids confers cardiovascular benefit in high-risk patients with the modest hypertriglyceridemia...However, it raises a number of questions including understanding the mechanism underscoring this benefit, how best to use these therapies and whether similar results will be observed with alternative omega-3 fatty acid preparations. Contemporary clinical trials of omega-3 fatty acids and their attempt to prevent cardiovascular events will be reviewed.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Journal:  Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. (Pubmed Central) -  Oct 27, 2021   
    IPE is now approved as an adjunct to maximally tolerated statins to reduce CVD event risk in adults with triglyceride (TG) levels ≥150 mg/dl and either established CVD or diabetes mellitus plus ≥2 additional CVD risk factors. The new indication allows co-administration of IPE for elevated TG levels with statin treatment, enabling effective residual risk reduction in a broader at-risk population beyond what can be achieved with intensive low-density lipoprotein cholesterol control alone.
  • ||||||||||  lisinopril / Generic mfg.
    [VIRTUAL] Will the Real Sodium Stand Up! () -  Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_3257;    
    Applying the following formula to correct for triglycerides = Measured Na+ (Plasma triglycerides (g/L) x 0.002 ); measured serum sodium would have been expected to be 125 meq. Thus in cases of extremely high lipids, one must consider lab techniques for measuring serum sodium, as well as full lipid panel in the evaluation and treatment of factitious hyponatremia.
  • ||||||||||  icosapent ethyl / Generic mfg.
    [VIRTUAL] Icosapent Ethyl Versus Placebo In Outpatients With Covid-19: The Main Results Of PREPARE-IT 2 (Live) -  Oct 14, 2021 - Abstract #AHA2021AHA_6910;    
    P3
    The primary endpoint and secondary endpoints will be available by the AHA and will be presented. Safety and tolerability of the loading dose in this unique population will be assessed and presented.CONCLUSIONSPREPARE-IT 2 will provide insight into whether or not icosapent ethyl is useful in preventing disease progression in symptomatic COVID-19 positive outpatients, as well as whether there is any effect on patient-reported symptoms.TRIAL REGISTRATIONThe PREPARE-IT 2 Trial; NCT04460651.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Enrollment open, Trial initiation date, IO biomarker:  Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases (clinicaltrials.gov) -  Sep 27, 2021   
    P=N/A,  N=250, Recruiting, 
    While icosapent ethyl demonstrated a benefit in these patients, drug class effect cannot be assumed and further investigations are warranted to examine the effects of other omega-3 agents at high doses. Not yet recruiting --> Recruiting | Initiation date: Jan 2021 --> Sep 2021
  • ||||||||||  icosapent ethyl / Generic mfg.
    Review, Journal:  Icosapent ethyl: scientific and legal controversies. (Pubmed Central) -  Sep 25, 2021   
    The story of the development of icosapent ethyl has been fraught with challenges, including the invalidation of six core patents on the product, and recently, the completion of a new clinical trial, STRENGTH (Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia), that directly contradicts REDUCE-IT and calls into question whether icosapent ethyl is actually effective in the secondary prevention of cardiovascular events. This article traces the course of the development of this fascinating product and discusses its complex medical, regulatory and legal history, which is still continuing to unfold.
  • ||||||||||  icosapent ethyl / Generic mfg.
    Journal:  The role of icosapent ethyl in cardiovascular risk reduction. (Pubmed Central) -  Sep 23, 2021   
    This review summarizes the results from outcome trials conducted with omega-3 fatty acids, differentiating between those with combinations of EPA/DHA and those with pure EPA, as well as imaging and preclinical data that help explain the different cardiovascular efficacy observed. A list of frequently asked questions with evidence-based responses is provided to assist our colleagues and their patients in the shared-decision process when considering if IPE is appropriate for cardiovascular risk reduction.